General Information
Revision date
2022-03-02
Product name
DYAZIDE CAPSULES
Product Synonyms
DYAZIDE CAPSULES 25 MG/37.5 MG * TRIAMTERENE AND HYDROCHLOROTHIAZIDE, FORMULATED PRODUCT
1.2.2. Uses advised against
No other uses are advised
Emergency telephone
+1-612-221-3999, Ext 221
Icons in SDS
Company Information
company name
GlaxoSmithKline
e-mail address of the competent person responsible for the Safety Data Sheet
msds@gsk.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H335
Hazard statements
Code
Statements
H335
May cause respiratory irritation
Section 2
Physical hazards
Not classified.
Health hazards
Specific target organ toxicity following single Category 3 respiratory tract irritation exposure
Environmental hazards
Not classified.
Signal word
Warning
Hazard statements
H335 May cause respiratory irritation.
Prevention
P261 Avoid breathing dust. P261 Avoid breathing vapours. P271 Use only outdoors or in a well-ventilated area.
Response
P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing. P312 Call a POISON CENTRE/doctor if you feel unwell.
Storage
P403 + P233 Store in a well-ventilated place. Keep container tightly closed. P405 Store locked up.
Disposal
P501 Dispose of contents/container in accordance with local/regional/national/international regulations.
Other hazards which do not result in classification
Caution - Pharmaceutical agent. See section 11 of the SDS for additional information on health hazards.
Additional information
7 % of the mixture consists of component(s) of unknown acute oral toxicity. 99 % of the mixture consists of component(s) of unknown acute dermal toxicity. 99 % of the mixture consists of component(s) of unknown acute inhalation toxicity. 99 % of the mixture consists of component(s) of unknown acute hazards to the aquatic environment. 99 % of the mixture consists of component(s) of unknown long-term hazards to the aquatic environment. National/local information Not available
